Advertisement

Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats

  • O. Curet
  • G. Damoiseau
  • J.-P. Labaune
  • V. Rovel
  • F.-X. Jarreau
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)

Summary

Single administration of befloxatone (0.75 mg/kg, i.p.) in the rat increased extracellular levels of DA (+300%) in striatum. In frontal cortex, befloxatone (0.75 mg/kg, i.p.) and nialamide (100 mg/kg, i.p.) increased NA by +100% but did not modify 5HT, whereas pargyline (100 mg/kg i.p.) increased extracellular NA and 5HT by 400 and 600%, respectively. At these doses, befloxatone inhibited totally and selectively MAO-A, pargyline inhibited totally MAO-A and MAO-B. Increases of tissue and extracellular concentrations of NA and 5HT were highest after Pargyline suggesting that both monoamines may be metabolized by MAO-A and MAO-B. Befloxatone and nialamide potentiated the effects of idazoxan (20 mg/kg, i.p.) on extracellular NA in frontal cortex, which increased from 350% to 2,000 and 1,500% respectively. These results suggest that α2-adrenoceptors play a major role in the regulation of extracellular NA in frontal cortex.

Keywords

Frontal Cortex Extracellular Level Octanesulfonic Acid Frontal Cortex Sample Extracellular DOPAC 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Caille D, Adam R, Bergis OE, Fankhauser C, Gardes A, Martin P (1992) Pharmacological profile of befloxatone, a new reversible MAO-A inhibitor. Proceedings XVIII CINP, Nice. Clin Neuropharmacol 15: 423B.Google Scholar
  2. Curet O, Damoiseau G, Aubin N (1992) Biochemical profile of befloxatone, a new reversible MAO-A inhibitor. Proceedings XVIII CINP, Nice. Clin Neuropharmacol 15: 424B.Google Scholar
  3. Dennis T, L’Heureux R, Carter C, Scatton B (1987) Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther 241: 642–649.PubMedGoogle Scholar
  4. Rovei V, Caille D, Curet O, Ego D, Jarreau FX (1994) Biochemical pharmacology of befloxatone (MD 370503), a new potent, reversible MAO-A inhibitor. J Neural Transm [Suppl] 41 (this volume).Google Scholar
  5. Strolin Benedetti M, Dostert P, Boucher T, Guffroy C (1982) A new reversible selective type B monoamine oxidase inhibitor, MD780236. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase: basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 209–220.Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • O. Curet
    • 1
  • G. Damoiseau
    • 1
  • J.-P. Labaune
    • 1
  • V. Rovel
    • 1
  • F.-X. Jarreau
    • 1
  1. 1.Synthelabo RechercheRueil MalmaisonFrance

Personalised recommendations